FindTrial
Sign In

Rapcabtagene autoleucel

BIOLOGICAL5 trials

Sponsors

Novartis Pharmaceuticals

Conditions

ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory MyopathiesLupus Erythematosus, SystemicLupus NephritisRheumatoid Arthritis (RA) and Sjögren's Disease (SjD)Scleroderma, Diffuse

Phase 1

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Active, not recruitingNCT07048197
Novartis PharmaceuticalsRheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Start: 2025-06-20End: 2028-11-01Target: 27Updated: 2026-09-04

Phase 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Active, not recruitingNCT06581198
Novartis PharmaceuticalsLupus Erythematosus, Systemic, Lupus Nephritis
Start: 2024-09-04End: 2032-02-06Target: 179Updated: 2026-09-02
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Active, not recruitingNCT06655896
Novartis PharmaceuticalsScleroderma, Diffuse
Start: 2024-10-29End: 2032-08-30Target: 96Updated: 2026-09-02
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Active, not recruitingNCT06665256
Novartis PharmaceuticalsIdiopathic Inflammatory Myopathies
Start: 2024-12-17End: 2032-11-29Updated: 2026-06-23
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Active, not recruitingNCT06868290
Novartis PharmaceuticalsANCA Associated Vasculitis (AAV)
Start: 2025-03-13End: 2030-05-24Target: 126Updated: 2026-09-04